DISCUSSION BPC 157 was suggested to be a link between inflammatory bowel disease and multiple sclerosis, that could be also used in practice per-orally (as an anti-ulcer peptide, stable in human gastric juice) (5-7, 9), and thereby, being equally effective against the models of both of those diseases
Long-term deficiency could potentially lead to nerve damage
The FDA Confronts a Market That Already Exists On July 23 and 24, 2026, an FDA advisory committee will begin examining whether seven peptide compounds should become eligible for pharmacy compounding
A more evidence-based way to evaluate whether something is helping is to track measurable outcomes with your clinician (for example, symptoms tied to confirmed deficiency, or objective metrics like body weight, waist measurements, and lab work when appropriate)